Basilea Pharmaceutica has licensed rights to its antifungal drug, Cresemba® (isavucanazole), to Pfizer in Europe (excluding Nordic countries), Russia, Turkey and Israel for US$72 M upfront and up to US$427 M in milestone payments. Basilea has partnered, marketed drugs Cresemba and Zevtera (ceftobiprolemedocaril)® with a number of companies in specific regions to increase their global reach and increase sales, giving the Swiss company the finances to advance its anti-infective and oncology-based pipeline.